Kwon Douglas S, Mylonakis Eleftherios
Massachusetts General Hospital, Division of Infectious Diseases, 55 Fruit Street, Boston, MA 02114-2696, USA.
Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. doi: 10.1517/14656566.8.8.1167.
The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical efficacy in the treatment of oropharyngeal candidiasis and has shown promise as salvage therapy for invasive aspergillosis, zygomycosis, cryptococcal meningitis and a variety of other fungal infections. In addition, data from randomized controlled studies support its efficacy for use in prophylaxis of invasive fungal infections in patients who are severely immunocompromised. The wide spectrum activity of posaconazole in in vitro studies, animal models and preliminary clinical studies suggest that posaconazole represents an important addition to the antifungal armamentarium.
侵袭性真菌感染发病率的上升以及更广泛的真菌耐药性的出现，使得需要新型抗真菌药物。泊沙康唑是三唑类抗真菌药物的新成员。它有口服混悬液剂型，毒性特征良好，已证明在治疗口咽念珠菌病方面具有临床疗效，并且作为侵袭性曲霉病、毛霉病、隐球菌性脑膜炎和多种其他真菌感染的挽救疗法显示出前景。此外，随机对照研究的数据支持其在严重免疫功能低下患者中用于预防侵袭性真菌感染的疗效。泊沙康唑在体外研究、动物模型和初步临床研究中的广泛活性表明，泊沙康唑是抗真菌药物库中的一项重要补充。
